Lilly and ProQR to Expand RNA Editing Collaboration
INDIANAPOLIS; LEIDEN, Netherlands; and CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) — Eli Lilly and Company (NYSE:LLY) and ProQR Therapeutics N.V. (Nasdaq:PRQR), today announced the expansion of their licensing and collaboration agreement focused on the discovery, development and commercialization of new genetic medicines.
Related news for (PRQR)
- ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
- ProQR to Present at Upcoming Scientific and Industry Conferences
- ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform
- ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform